Cellectar Biosciences
Business Services · New Jersey, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
100 Campus Dr Ste 207, Florham Park, New...Phone Number
(608) 441-8120Website
www.cellectar.comRevenue
-Stock Symbol
CLRBIndustry
ZI Rank: 2
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
2
About Cellectar Biosciences
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.Explore more
Cellectar Biosciences Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cellectar Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Cellectar Biosciences had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Cellectar Biosciences has new funding data
Product Launch: Get notified when Cellectar Biosciences launches new products
Check if Cellectar Biosciences has recently received funding, and reach out quickly before it becomes old news!
Cellectar Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Cellectar Biosciences recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Cellectar Biosciences
Check out if Cellectar Biosciences is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Cellectar Biosciences
Compare insights from companies similar to Cellectar Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cellectar Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cellectar Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cellectar Biosciences.
Cellectar Biosciences financials insights
Gather financial insights about Cellectar Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2016
Stock Offering
$9.2M
2017
Stock Offering
$7.8M
2018
Stock Offering
$16.6M
2019
Stock Offering
$10M
2020
Debt
$150K
2023
Share Placement
$102.9M
2025
Stock/Share Issuance
$2.5M
Cellectar Biosciences Tech Stack
A closer look at the technologies used by Cellectar Biosciences
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Earnings, Spending/Investment, Finance, Financial Operations
Cellectar Biosciences News & Media
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
FLORHAM PARK, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that the Company will report financial results for the second quarter ended June 30, 2026, and provide a corporate update on August 13, 2026, at 8:30 a.m. Eastern Time.Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Demonstrated Favorable Safety Profile and Preliminary Clinical Activity in Relapsed/Refractory Multiple MyelomaCellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk
Cellectar Biosciences is back in focus after its fair value estimate was reset from US$76.00 to about US$10.33, a sharp shift that lines up more closely with the latest US$10 analyst price target. Recent research commentary links this change to a mix of optimism around that US$10 target and caution about how the company delivers against the assumptions behind it. As you read on, you will see how this evolving price target story shapes theCellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Cellectar Biosciences
Sign Up For FreeTo access detailed company insights
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study fo... Read More
